NCT04058834View on ClinicalTrials.gov

A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

April 23, 2020

Study Completion Date

April 23, 2020

Conditions
Healthy VolunteersHypercholesterolaemia
Interventions
DRUG

NNC0385-0434

Healthy volunteers and patients will receive one injection s.c. (subcutaneously, under the skin)

DRUG

Placebo (NNC0385-0434)

Healthy volunteers will receive one injection s.c.

Trial Locations (1)

HA1 3UJ

Novo Nordisk Investigational Site, Harrow

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY